Patents Issued in November 30, 2017
  • Publication number: 20170340667
    Abstract: Compositions and methods for treating tar-responsive dermatological disorders are described. In particular, an anhydrous tar composition including a liquid wax and a therapeutically effective amount of tar in an anhydrous solvent, the composition being in liquid form at room temperature is described. The anhydrous tar composition can be topically applied to skin of a subject for treatment of tar-responsive dermatological disorders, such as psoriasis, eczema, atopic dermatitis, seborrheic dermatitis and pruritus.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 30, 2017
    Inventors: Ruey J. YU, Eugene J. VAN SCOTT, Yaling LEE
  • Publication number: 20170340668
    Abstract: Disclosed are a novel pharmaceutical composition and use thereof, the novel pharmaceutical composition at least comprising an effective amount of mitochondria and at least one pharmaceutically acceptable carrier; the novel pharmaceutical composition is administered to an individual to send the mitochondria into injured or subject-to-oxidative-stress lung cells; thus treating or improving lung injury or related diseases thereof.
    Type: Application
    Filed: December 31, 2014
    Publication date: November 30, 2017
    Applicant: Taiwan Mitochondrion Applied Technology Co., Ltd.
    Inventor: Hong-Lin SU
  • Publication number: 20170340669
    Abstract: Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 30, 2017
    Inventors: Lenka PALOVÁ JELÍNKOVÁ, Klára DÁÑOVÁ, Radek SPÍSEK
  • Publication number: 20170340670
    Abstract: A conditioned cell culture medium of CD11blow human macrophages or a biologically active fraction thereof can be prepared by a method that includes (i) culturing a population of human mononuclear cells of the monocyte/macrophage lineage for 5-7 days, so as to induce differentiation of the mononuclear cells to macrophages; (ii) incubating the macrophages obtained in (i) with apoptotic cells or in the presence of a pro-resolving lipid mediator to reduce the CD11b expression, thus obtaining a culture of CD11blow macrophages; and (iii) collecting the conditioned cell culture medium of CD11blow macrophages. Pharmaceutical compositions containing the CD11blow macrophages conditioned medium or a culture of CD11blow macrophages can be used in the treatment of cancer or fibrosis.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 30, 2017
    Inventors: Dalit Barkan, Odelya Gilon, Amiram Ariel, Sagie Schif-Zuck, Aroesti-Assi Simaan
  • Publication number: 20170340671
    Abstract: The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.
    Type: Application
    Filed: April 27, 2017
    Publication date: November 30, 2017
    Inventors: Steven P. Braithwaite, S. Sakura Minami, Joseph McCracken
  • Publication number: 20170340672
    Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 30, 2017
    Inventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
  • Publication number: 20170340673
    Abstract: The present invention relates to the use of the intracellular content of mesenchymal stem cells in individuals for stimulating the survival, regeneration and/or repair of the damaged organ and/or tissue. The present invention also relates to the use of said lysate for producing a pharmaceutical composition comprising said intracellular content, and to the use thereof in the regeneration and/or repair of the damaged organ and/or tissue.
    Type: Application
    Filed: November 6, 2015
    Publication date: November 30, 2017
    Inventors: Juan Rafael MUÑOZ CASTAÑEDA, Juan Manuel DÍAZ TOCADOS, Juan Manuel DOMÍNGUEZ PÉREZ
  • Publication number: 20170340674
    Abstract: The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.
    Type: Application
    Filed: December 22, 2015
    Publication date: November 30, 2017
    Applicant: Mesoblast International Sàrl
    Inventors: Silviu Itescu, Lee Golden
  • Publication number: 20170340675
    Abstract: A method for the treatment of acute stroke in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 30, 2017
    Inventors: Bernard Sze Piaw Chin, Kong Yong Then, Soon Keng Cheong
  • Publication number: 20170340676
    Abstract: The present invention relates to a cell-based composition comprising a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml. The cell-based composition is used in a form of medicament for treatment of diabetes and its associated metabolic disorders and complications.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 30, 2017
    Inventors: Bernard Sze Piaw Chin, Kong Yong Then, Soon Keng Cheong
  • Publication number: 20170340677
    Abstract: The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.
    Type: Application
    Filed: December 11, 2015
    Publication date: November 30, 2017
    Applicant: KEIO UNIVERSITY
    Inventors: Shigeto SHIMMURA, Shin HATOU, Kazuo TSUBOTA
  • Publication number: 20170340678
    Abstract: Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may include providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardic explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided.
    Type: Application
    Filed: May 30, 2017
    Publication date: November 30, 2017
    Inventors: Duncan J. Stewart, David Courtman, Seth Mount, Darryl Davis
  • Publication number: 20170340679
    Abstract: Disclosed herein are compositions and methods for treating a victim of a venomous snakebite. Antivenom compositions are prepared from snake plasma or from snake eggs. The antivenom compositions are able to neutralize a snake venom from an autologous snake. The antivenom compositions can be administered to a snakebite victim to treat or prevent the pathological effects of a venomous snakebite.
    Type: Application
    Filed: May 24, 2017
    Publication date: November 30, 2017
    Inventor: Donald SCHULTZ
  • Publication number: 20170340680
    Abstract: The invention relates to the use of a composition comprising at least one extract of propolis, having at least one of the following properties:—an antioxidant value (ORAC) greater than or equal to 500 mmol TE/100 g of dry extract,—a flavones and flavonols content greater than or equal to 5.5% by weight with respect to the total weight of dry material of the extract,—a flavanones and dihydroflavanols content greater than or equal to 5% by weight with respect to the total weight of dry material of the product, in order to prevent and/or limit the side effects of chemotherapy.
    Type: Application
    Filed: December 11, 2015
    Publication date: November 30, 2017
    Inventor: Nicolas CARDINAULT
  • Publication number: 20170340681
    Abstract: A method of treating arthritis, which comprising administering to a subject in need an effective amount of Streptococcus thermophilus DSM 28121 strain. The method is especially used for relieving joint pain, alleviating joint swelling, relieving tissue inflammation, protecting cartilaginous tissues and increasing the number of chondrocytes in the cartilaginous tissues.
    Type: Application
    Filed: May 30, 2017
    Publication date: November 30, 2017
    Inventor: Yung-Hsiang LIN
  • Publication number: 20170340682
    Abstract: Bacillus strains, compositions and methods are disclosed for reducing growth of microorganisms in a feed. Bacillus strains, compositions and methods are disclosed for providing beneficial effects to animals, including but not limited to increasing performance of the animal.
    Type: Application
    Filed: May 25, 2017
    Publication date: November 30, 2017
    Inventors: Thomas Rehberger, John O'Neill, Alexandra Smith, Mari Ellen Davis, Jesse Thompson, Jennifer Schissel
  • Publication number: 20170340683
    Abstract: The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as a probiotic.
    Type: Application
    Filed: May 29, 2017
    Publication date: November 30, 2017
    Inventors: Daniel Petri, Stefan Pelzer, Jessica Schneider, Stella Molck, Maike Kipker, Claudia Borgmeier, Sandra Herbold, Guido Meurer, Rose Whelan, Kiran Doranalli
  • Publication number: 20170340684
    Abstract: The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell.
    Type: Application
    Filed: May 12, 2014
    Publication date: November 30, 2017
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Amin Hajitou, Teerapong Yata
  • Publication number: 20170340685
    Abstract: The present invention relates to a Myoviridae bacteriophage Clo-PEP-1 that is isolated from the nature and can kill Clostridium perfringens cells specifically, which has the genome represented by nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12664BP), and a method for preventing and treating the infections of Clostridium perfringens cells using the composition comprising said bacteriophage as an active ingredient.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 30, 2017
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Jee Soo Son, Hyoun Rok PAIK, Suk Hwang Park
  • Publication number: 20170340686
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12662BP), and a method for preventing and treating the infections of Shigatoxin-producing type F18 E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 30, 2017
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim
  • Publication number: 20170340687
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 30, 2017
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Publication number: 20170340688
    Abstract: The present invention relates to a titrated extract of Cynara scolymus, to titrated fractions of extract of Cynara scolymus or titrated mixtures of said extract with one or more of said titrated fractions or mixtures of said fractions, and to compositions and kits comprising them, for the prevention and/or the treatment of a pathological condition characterised by a constitutive activation of the STAT3 transcription factor,
    Type: Application
    Filed: November 24, 2015
    Publication date: November 30, 2017
    Inventor: Valentino MERCATI
  • Publication number: 20170340689
    Abstract: The present invention relates to a titrated extract of Cynara scolymus, to titrated fractions of extract of Cynara scolymus or titrated mixtures of said extract with one or more of said titrated fractions or mixtures of said fractions and to compositions and kits that comprise them for the prevention and/or the treatment of malignant pleural mesothelioma.
    Type: Application
    Filed: November 24, 2015
    Publication date: November 30, 2017
    Inventor: Valentino MERCATI
  • Publication number: 20170340690
    Abstract: Disclosed is a method for improving intestinal microflora, which includes administering an extract of Codonopsis lanceolata of an amount effective for improving intestinal microflora to a subject in need thereof. The extract can promote the proliferation of beneficial intestinal bacteria and suppress the proliferation of harmful bacteria. Also, the extract can improve intestinal health or intestinal function and improve defecation disorder. In addition, a synergic effect can be obtained when the composition of the present disclosure is used together with probiotics.
    Type: Application
    Filed: May 16, 2017
    Publication date: November 30, 2017
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Cheol-Ho PAN, Kyungsu KANG, Kwang-Hyun CHA, Eun Ha LEE, Hee Ju LEE, Song Yi KOO, Yongsoo CHOI
  • Publication number: 20170340691
    Abstract: The present invention provides an antimicrobial composition comprising at least one garlic extract and one or more of a bioflavonoid and/or an organic acid as well as the use of the same for treating or preventing bacterial, fungal or parasitic infections.
    Type: Application
    Filed: December 15, 2015
    Publication date: November 30, 2017
    Applicant: Neem Biotech Limited
    Inventors: Carl Jorg Michael GRAZ, Gareth James Street EVANS, Robert Alun SAUNDERS, Liam James JONES
  • Publication number: 20170340692
    Abstract: The present invention relates to a mixture of active ingredients consisting of Taraxacum officinalis, Fagopyrum esculentum, Ruscus aculeatus, Solidago virgaurea and Orthosiphon stamineus or extracts of said plants or from said plants and extracts thereof, a composition comprising such a mixture, and uses thereof.
    Type: Application
    Filed: January 4, 2016
    Publication date: November 30, 2017
    Inventors: Valentino MERCATI, Anna MAIDECCHI
  • Publication number: 20170340693
    Abstract: Haematopoietic stem cell mobilization is a process whereby haematopoietic stem cells are stimulated out of the bone marrow space. Before HSC can mobilize, they must be dislodged and released from the BM stem cell niche in which they reside and are retained by adhesive interactions. Accordingly, in an aspect of the present invention there is provided a method for enhancing dislodgement of HSC and their precursors and progenitors thereof from a BM stem cell binding ligand in vivo or ex vivo, said method comprising administering in vivo or ex vivo an effective amount of an antagonist of an ?9 integrin or an active portion thereof and a CXCR4 antagonist or an active portion thereof to the BM stem cell niche. Once mobilized to the peripheral blood (PB) the HSC may be collected for transplant. Methods which enhance mobilization of the HSC can also improve treatments of haematological disorders.
    Type: Application
    Filed: December 11, 2015
    Publication date: November 30, 2017
    Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Susan Kaye NILSSON, David Norman HAYLOCK, Benjamin Ben Ming CAO
  • Publication number: 20170340694
    Abstract: The present disclosure relates to a composition to aid in heavy metal detox. Metallothioneins (MT) are a family of cysteine-rich enzymes in the body that help remove and regulate heavy metals, copper, and other metals. Amino Acids in combination with zinc and/or molybdenum may provide improved production of MT over amino acid or zinc supplements alone. Additionally, Vitamin B6, Molybdenum, and Boron may be included to further enhance the efficacy of the composition.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Inventors: Stephen N. Pitcher, Danny Purser
  • Publication number: 20170340695
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Application
    Filed: April 17, 2017
    Publication date: November 30, 2017
    Inventor: D. Travis Wilson
  • Publication number: 20170340696
    Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with a cytotoxic chemotherapeutic agent that inhibits immune tolerance, wherein the chemotherapeutic agent is administered at a sub-cytotoxic dose.
    Type: Application
    Filed: November 4, 2015
    Publication date: November 30, 2017
    Inventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Oystein Rekdal, John Sigurd Mjoen Svendsen
  • Publication number: 20170340697
    Abstract: The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 30, 2017
    Inventors: Hamid Reza REZVANI, Frédéric MAZURIER, Alain TAIEB, L'Emira Ghida HARFOUCHE
  • Publication number: 20170340698
    Abstract: Provided is a cyclic peptide (cyclo [Cys-Gln-Arg-Pro-Pro-Arg-Cys] peptide) comprised of the amino acid sequence of SEQ ID NO: 2; and a composition for apoptotic cell detection, drug delivery or imaging, containing the same as an active ingredient. The cyclic peptide (cyclo [Cys-Gln-Arg-Pro-Pro-Arg-Cys] peptide has an excellent effect of binding to apoptotic cells, compared with a linear peptide thereof, thereby greatly facilitating the detection of apoptotic cells and the in vivo imaging of an affected part under apoptosis, while the detection and imaging signal shows a very high correlation in disease prognosis prediction. The cyclic peptide binds to an imaging material, early diagnosing a response of a drug for treating diseases associated with abnormal cell proliferation, and binds to a therapeutic material, selectively delivering a drug to tissues afflicted with Apoptosis-associated diseases.
    Type: Application
    Filed: June 2, 2017
    Publication date: November 30, 2017
    Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC CO OPERATION FOUNDATION
    Inventors: Byung-Heon LEE, In-San KIM, Hyun-Kyung JUNG
  • Publication number: 20170340699
    Abstract: This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.
    Type: Application
    Filed: January 6, 2015
    Publication date: November 30, 2017
    Inventor: NIKHIL V. DHURANDHAR
  • Publication number: 20170340700
    Abstract: The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (MDR) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which is derived from Nile Tilapia (Oreochromis niloticus). Also provided is a method for treating a breast cancer, particularly triple negative breast cancer (TNBC) with TP4.
    Type: Application
    Filed: January 11, 2017
    Publication date: November 30, 2017
    Inventors: Jyh-Yih CHEN, Chen-Hung TING
  • Publication number: 20170340701
    Abstract: Peptide system including at least one peptide blocking the presynaptic release of glutamate. The peptide has the sequence SEQ ID NO 5: GRKKRRQRRRPPIEQSIEQEEGLNRS and/or sequence SEQ ID NO 8: GRKKRRQRRRPPMSEYNATQSDYRER for use in treating pathologies associated with glutamate excitotoxicity.
    Type: Application
    Filed: July 24, 2017
    Publication date: November 30, 2017
    Inventors: Marco FELIGIONI, Robert Giovanni NISTICO'
  • Publication number: 20170340702
    Abstract: Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
    Type: Application
    Filed: May 31, 2017
    Publication date: November 30, 2017
    Applicant: CardioVax, LLC
    Inventors: Mark Carvlin, Jan Nilsson, Stacey Ruiz
  • Publication number: 20170340703
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.
    Type: Application
    Filed: June 5, 2017
    Publication date: November 30, 2017
    Applicant: Pieris Pharmaceuticals GmbH
    Inventors: Andreas HOHLBAUM, Alexandra BAEHRE, Gabriele MATSCHINER, Stefan TRENTMANN, Klaus KIRCHFELD, Hans-Juergen CHRISTIAN
  • Publication number: 20170340704
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Application
    Filed: June 23, 2017
    Publication date: November 30, 2017
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Publication number: 20170340705
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Application
    Filed: June 23, 2017
    Publication date: November 30, 2017
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Publication number: 20170340706
    Abstract: Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin.
    Type: Application
    Filed: June 7, 2017
    Publication date: November 30, 2017
    Inventors: Stanley T. CARMICHAEL, Andrew N. CLARKSON
  • Publication number: 20170340707
    Abstract: A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 30, 2017
    Applicant: Induce Biologics Inc.
    Inventors: Sean A.F. PEEL, Cameron M.L. CLOKIE
  • Publication number: 20170340708
    Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 30, 2017
    Inventors: Ting XU, Yan LUAN, Jianjian PENG, Shuli MA, Meng ZHAO, Xiaoxiao WANG, Hui MA, Shilong FU, Xiolong PAN, Shanshan NING
  • Publication number: 20170340709
    Abstract: The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer.
    Type: Application
    Filed: September 1, 2016
    Publication date: November 30, 2017
    Inventor: Andrew MacGregor Cameron
  • Publication number: 20170340710
    Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 30, 2017
    Inventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
  • Publication number: 20170340711
    Abstract: A scaffold for promoting cartilage formation is provided that includes a crosslinked electrospun fiber, wherein the crosslinked electrospun fiber consists essentially of crosslinked gelatin. The crosslinked electrospun fiber is generally crosslinked with a crosslinker, and the crosslinker may be diisosorbide bisepoxide. The crosslinked electrospun fiber may be crosslinked by adding a crosslinker to a solution of gelatin at a desired concentration. The electrospun fiber may advantageously remain intact for 18 days or longer upon being immersed in an aqueous solution. A composition for promoting cartilage formation is also provided that includes the disclosed scaffold and a mesenchymal stem cell (MSC). The disclosed scaffold may include a crosslinked electrospun fiber that includes gelatin and sodium cellulose sulfate (NaCS), e.g., in an amount of up to 5% by weight of the amount of gelatin.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 30, 2017
    Applicant: New Jersey Institute of Technology
    Inventors: Tamilvizhi Muthalagu, George Collins, Treena L. Arinzeh
  • Publication number: 20170340712
    Abstract: Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue.
    Type: Application
    Filed: May 31, 2017
    Publication date: November 30, 2017
    Applicants: SUMMA HEALTH, NORTHEAST OHIO MEDICAL UNIVERSITY
    Inventors: Marc S. PENN, Matthew KIEDROWSKI, Maritza MAYORGA
  • Publication number: 20170340713
    Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 30, 2017
    Inventors: Demetrios BRADDOCK, Ronald ALBRIGHT
  • Publication number: 20170340714
    Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 30, 2017
    Inventors: Demetrios BRADDOCK, Ronald ALBRIGHT
  • Publication number: 20170340715
    Abstract: The present invention provides compositions and methods useful for treating cancers such as glioblastoma. SapC-DOPS was found to be synergistically effective at inducing cell death when administered in conjunction with rampamycin. SapC-DOPS/rapamycin combination therapy allows physicians to give lower doses of each drug and achieve better therapeutic efficacy. The compositions also allow for less toxicity and fewer off-target effects. Related methods and materials are also provided herein.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 30, 2017
    Applicants: Ohio State Innovation Foundation, University of Cincinnati
    Inventors: Balveen Kaur, Jeffrey Wojton, Xiaoyang Qi
  • Publication number: 20170340716
    Abstract: The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.
    Type: Application
    Filed: June 19, 2017
    Publication date: November 30, 2017
    Inventor: David S. Wilkes